Search

Your search keyword '"Fantozzi, Roberta"' showing total 211 results
Start Over Author "Fantozzi, Roberta"
211 results on '"Fantozzi, Roberta"'

2. The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT)

Author

Bianchi, Alessia, Matranga, Domenica, Patti, Francesco, Maniscalco, Laura, Pilotto, Silvy, Di Filippo, Massimiliano, Zaffaroni, Mauro, Annovazzi, Pietro, Bertolotto, Antonio, Gasperini, Claudio, Quartuccio, Esmeralda, Centonze, Diego, Fantozzi, Roberta, Gajofatto, Alberto, Gobbin, Francesca, Landi, Doriana, Granella, Franco, Buccafusca, Maria, Marfia, Girolama Alessandra, Chisari, Clara, Naldi, Paola, Bergamaschi, Roberto, Greco, Giacomo, Zarbo, Ignazio Roberto, Rizzo, Vincenzo, Ulivelli, Monica, Bezzini, Daiana, Florio, Lucia, Turazzini, Michelangelo, Di Gregorio, Maria, Pugliatti, Maura, Salemi, Giuseppe, and Ragonese, Paolo

Published
2024
Full Text
View/download PDF

3. SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose

Author

Di Filippo, Massimiliano, Ferraro, Diana, Ragonese, Paolo, Prosperini, Luca, Maniscalco, Giorgia Teresa, Gallo, Antonio, Cavalla, Paola, Lorefice, Lorena, Nociti, Viviana, Di Sabatino, Elena, Clerico, Marinella, Guaschino, Clara, Radaelli, Marta, Fantozzi, Roberta, Buttari, Fabio, Laroni, Alice, Gajofatto, Alberto, Calabrese, Massimiliano, Malucchi, Simona, Paolicelli, Damiano, De Luca, Giovanna, Tomassini, Valentina, Lanzillo, Roberta, Moccia, Marcello, Solaro, Claudio, Cocco, Eleonora, Gasperini, Claudio, and Tortorella, Carla

Published
2024
Full Text
View/download PDF

4. NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab

Author

Signoriello, Elisabetta, Signori, Alessio, Lus, Giacomo, Romano, Giuseppe, Marfia, Girolama Alessandra, Landi, Doriana, Napoli, Francesca, D' Amico, Emanuele, Zanghí, Aurora, Di Filippo, Paola Sofia, Caliendo, Daniele, Carotenuto, Antonio, Spiezia, Antonio Luca, Fantozzi, Roberta, Centonze, Diego, Lucchini, Matteo, Mirabella, Massimiliano, Cocco, Eleonora, Frau, Jessica, Maniscalco, Giorgia Teresa, Di Battista, Maria Elena, Foschi, Matteo, Surcinelli, Andrea, Bonavita, Simona, Abbadessa, Gianmarco, Pasquali, Livia, Di Gregorio, Maria, Ferrò, Maria Teresa, Sormani, Maria Pia, and Schiavetti, Irene

Published
2024
Full Text
View/download PDF

5. Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience

Author

Ruggieri, Serena, Ianniello, Antonio, Copetti, Massimiliano, Altieri, Marta, Buscarinu, Maria Chiara, Centonze, Diego, Cortese, Antonio, De Giglio, Laura, Fantozzi, Roberta, Gasperini, Claudio, Grimaldi, Luigi M.E., Landi, Doriana, Marfia, Girolama A., Mirabella, Massimiliano, Nistri, Riccardo, Nociti, Viviana, Oddo, Oscar, Romano, Silvia, Salemi, Giuseppe, Tortorella, Carla, Pozzilli, Carlo, and Petracca, Maria

Published
2024
Full Text
View/download PDF

6. Patients with multiple sclerosis choose a collaborative role in making treatment decision: results from the Italian multicenter SWITCH study

Author

Patti, Francesco, Chisari, Clara Grazia, Toscano, Simona, Annovazzi, Pietro, Banfi, Paola, Bergamaschi, Roberto, Clerici, Raffaella, Conti, Marta Zaffira, Cortese, Antonio, Fantozzi, Roberta, Ferraro, Diana, Fischetti, Mariano, Frigo, Maura, Gatto, Maurizia, Immovilli, Paolo, Leoni, Stefania, Malucchi, Simona, Maniscalco, Giorgia, Marfia, Girolama Alessandra, Paolicelli, Damiano, Perini, Paola, Serrati, Carlo, Totaro, Rocco, Turano, Gabriella, Valentino, Paola, Zaffaroni, Mauro, Zuliani, Cristina, and Centonze, Diego

Published
2023
Full Text
View/download PDF

7. Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study

Author

Petracca, Maria, Ruggieri, Serena, Barbuti, Elena, Ianniello, Antonio, Fantozzi, Roberta, Maniscalco, Giorgia Teresa, Andreone, Vincenzo, Landi, Doriana, Marfia, Girolama Alessandra, Di Gregorio, Maria, Iodice, Rosa, Sinisi, Leonardo, Maida, Elisabetta, Missione, Rosanna, Coppola, Cinzia, Bonavita, Simona, Borriello, Giovanna, Centonze, Diego, Lus, Giacomo, Pozzilli, Carlo, and Signoriello, Elisabetta

Published
2022
Full Text
View/download PDF

8. Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis

Author

Sanna, Krizia, primary, Bruno, Antonio, additional, Balletta, Sara, additional, Caioli, Silvia, additional, Nencini, Monica, additional, Fresegna, Diego, additional, Guadalupi, Livia, additional, Dolcetti, Ettore, additional, Azzolini, Federica, additional, Buttari, Fabio, additional, Fantozzi, Roberta, additional, Borrelli, Angela, additional, Stampanoni Bassi, Mario, additional, Gilio, Luana, additional, Lauritano, Gianluca, additional, Vanni, Valentina, additional, De Vito, Francesca, additional, Tartacca, Alice, additional, Mariani, Fabrizio, additional, Rovella, Valentina, additional, Musella, Alessandra, additional, Centonze, Diego, additional, and Mandolesi, Georgia, additional

Published
2024
Full Text
View/download PDF

9. Interleukin-10 contrasts inflammatory synaptopathy and central neurodegenerative damage in multiple sclerosis.

Author

Gilio, Luana, Fresegna, Diego, Bassi, Mario Stampanoni, Musella, Alessandra, De Vito, Francesca, Balletta, Sara, Sanna, Krizia, Caioli, Silvia, Pavone, Luigi, Galifi, Giovanni, Simonelli, Ilaria, Guadalupi, Livia, Vanni, Valentina, Buttari, Fabio, Dolcetti, Ettore, Bruno, Antonio, Azzolini, Federica, Borrelli, Angela, Fantozzi, Roberta, and Finardi, Annamaria

Subjects
MEDIUM spiny neurons, INTERLEUKIN-10, BRAIN anatomy, LABORATORY mice, MULTIPLE sclerosis, NEURAL transmission
Abstract

Proinflammatory cytokines are implicated in promoting neurodegeneration in multiple sclerosis (MS) by affecting excitatory and inhibitory transmission at central synapses. Conversely, the synaptic effects of anti-inflammatory molecules remain underexplored, despite their potential neuroprotective properties and their presence in the cerebrospinal fluid (CSF) of patients. In a study involving 184 newly diagnosed relapsing-remitting (RR)-MS patients, we investigated whether CSF levels of the anti-inflammatory interleukin (IL)-10 were linked to disease severity and neurodegeneration measures. Additionally, we examined IL-10 impact on synaptic transmission in striatal medium spiny neurons and its role in counteracting inflammatory synaptopathy induced by IL-1β in female C57BL/6 mice with experimental autoimmune encephalomyelitis (EAE). Our findings revealed a significant positive correlation between IL-10 CSF levels and changes in EDSS (Expanded Disability Status Scale) scores one year after MS diagnosis. Moreover, IL-10 levels in the CSF were positively correlated with volumes of specific subcortical brain structures, such as the nucleus caudate. In both MS patients' CSF and EAE mice striatum, IL-10 and IL-1β expressions were upregulated, suggesting possible antagonistic effects of these cytokines. Notably, IL-10 exhibited the ability to decrease glutamate transmission, increase GABA transmission in the striatum, and reverse IL-1β-induced abnormal synaptic transmission in EAE. In conclusion, our data suggest that IL-10 exerts direct neuroprotective effects in MS patients by modulating both excitatory and inhibitory transmission and attenuating IL-1β-induced inflammatory synaptopathy. These findings underscore the potential therapeutic significance of IL-10 in mitigating neurodegeneration in MS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study

Author

Bucello, Sebastiano, Annovazzi, Pietro, Ragonese, Paolo, Altieri, Marta, Barcella, Valeria, Bergamaschi, Roberto, Bianchi, Alessia, Borriello, Giovanna, Buscarinu, Maria Chiara, Callari, Graziella, Capobianco, Marco, Capone, Fioravante, Cavalla, Paola, Cavarretta, Rosella, Cortese, Antonio, De Luca, Giovanna, Di Filippo, Massimiliano, Dattola, Vincenzo, Fantozzi, Roberta, Ferraro, Elisabetta, Filippi, Maria Maddalena, Gasperini, Claudio, Grimaldi, Luigi Maria Edoardo, Landi, Doriana, Re, Marianna Lo, Mallucci, Giulia, Manganotti, Paolo, Marfia, Girolama Alessandra, Mirabella, Massimiliano, Perini, Paola, Pisa, Marco, Realmuto, Sabrina, Russo, Margherita, Tomassini, Valentina, Torri-Clerici, Valentina Liliana Adriana, Zaffaroni, Mauro, Zuliani, Cristina, Zywicki, Sofia, Filippi, Massimo, and Prosperini, Luca

Published
2021
Full Text
View/download PDF

12. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis

Author

Lucchini, Matteo, Prosperini, Luca, Buscarinu, Maria Chiara, Centonze, Diego, Conte, Antonella, Cortese, Antonio, Elia, Giorgia, Fantozzi, Roberta, Ferraro, Elisabetta, Gasperini, Claudio, Ianniello, Antonio, Landi, Doriana, Marfia, Girolama Alessandra, Nociti, Viviana, Pozzilli, Carlo, Salvetti, Marco, Tortorella, Carla, and Mirabella, Massimiliano

Published
2021
Full Text
View/download PDF

14. Re-emergence of T lymphocytemediated synaptopathy in progressive multiple sclerosis.

Author

Sanna, Krizia, Bruno, Antonio, Balletta, Sara, Caioli, Silvia, Nencini, Monica, Fresegna, Diego, Guadalupi, Livia, Dolcetti, Ettore, Azzolini, Federica, Buttari, Fabio, Fantozzi, Roberta, Borrelli, Angela, Bassi, Mario Stampanoni, Gilio, Luana, Lauritano, Gianluca, Vanni, Valentina, De Vito, Francesca, Tartacca, Alice, Mariani, Fabrizio, and Rovella, Valentina

Subjects
MULTIPLE sclerosis, T cells, NEURAL transmission, DISEASE relapse, SYNAPSES
Abstract

Background: Secondary progressive multiple sclerosis (SPMS) is defined by the irreversible accumulation of disability following a relapsing-remitting MS (RRMS) course. Despite treatments advances, a reliable tool able to capture the transition from RRMS to SPMS is lacking. A T cell chimeric MS model demonstrated that T cells derived from relapsing patients exacerbate excitatory transmission of central neurons, a synaptotoxic event absent during remitting stages. We hypothesized the re-emergence of T cell synaptotoxicity during SPMS and investigated the synaptoprotective effects of siponimod, a sphingosine 1-phosphate receptor (S1PR) modulator, known to reduce grey matter damage in SPMS patients. Methods: Data from healthy controls (HC), SPMS patients, and siponimod-treated SPMS patients were collected. Chimeric experiments were performed incubating human T cells on murine cortico-striatal slices, and recording spontaneous glutamatergic activity from striatal neurons. Homologous chimeric experiments were executed incubating EAE mice T cells with siponimod and specific S1PR agonists or antagonists to identify the receptor involved in siponimod-mediated synaptic recovery. Results: SPMS patient-derived T cells significantly increased the striatal excitatory synaptic transmission (n=40 synapses) compared to HC T cells (n=55 synapses), mimicking the glutamatergic alterations observed in active RRMS-T cells. Siponimod treatment rescued SPMS T cells synaptotoxicity (n=51 synapses). Homologous chimeric experiments highlighted S1P5R involvement in the siponimod’s protective effects. Conclusion: Transition from RRMS to SPMS involves the reappearance of T cell-mediated synaptotoxicity. Siponimod counteracts T cell-induced excitotoxicity, emphasizing the significance of inflammatory synaptopathy in progressive MS and its potential as a promising pharmacological target. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop).

Author

Schiavetti, Irene, Signori, Alessio, Albanese, Angela, Frau, Jessica, Cocco, Eleonora, Lorefice, Lorena, di Lemme, Sonia, Fantozzi, Roberta, Centonze, Diego, Landi, Doriana, Marfia, Girolama, Signoriello, Elisabetta, Lus, Giacomo, Zecca, Chiara, Gobbi, Claudio, Iodice, Rosa, Malimpensa, Leonardo, Cordioli, Cinzia, Ferraro, Diana, and Ruscica, Francesca

Subjects
OLDER patients, DISEASE relapse, MULTIPLE sclerosis, CHRONIC hepatitis B
Abstract

Background and purpose: Cladribine tablets, a purine analogue antimetabolite, offer a unique treatment regimen, involving short courses at the start of the first and second year, with no further treatment needed in years 3 and 4. However, comprehensive evidence regarding patient outcomes beyond the initial 24 months of cladribine treatment is limited. Methods: This retrospective, multicenter study enrolled 204 patients with multiple sclerosis who had completed the 2‐year course of cladribine treatment. The primary outcomes were therapeutic choices and clinical disease activity assessed by annualized relapse rate after the 2‐year treatment course. Results: A total of 204 patients were enrolled; most patients (75.4%) did not initiate new treatments in the 12 months postcladribine. The study found a significant reduction in annualized relapse rate at the 12‐month follow‐up after cladribine completion compared to the year prior to starting therapy (0.07 ± 0.25 vs. 0.82 ± 0.80, p < 0.001). Furthermore, patients with relapses during cladribine treatment were more likely to start new therapies, whereas older patients were less likely. The safety profile of cladribine was favorable, with lymphopenia being the primary registered adverse event. Conclusions: This study provides insights into therapeutic choices and disease activity following cladribine treatment. It highlights cladribine's effectiveness in reducing relapse rates and disability progression, reaffirming its favorable safety profile. Real‐world data, aligned with previous reports, draw attention to ocrelizumab and natalizumab as common choices after cladribine. However, larger, prospective studies for validation and a more comprehensive understanding of cladribine's long‐term impact are necessary. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis.

Author

Aprea, Maria Grazia, Schiavetti, Irene, Portaccio, Emilio, Ballerini, Chiara, Bonavita, Simona, Buscarinu, Maria, Calabrese, Massimiliano, Cavalla, Paola, Cellerino, Maria, Cordioli, Cinzia, Dattola, Vincenzo, De Biase, Stefano, De Meo, Ermelinda, Fantozzi, Roberta, Gallo, Antonio, Iasevoli, Luigi, Karabudak, Rana, Landi, Doriana, Lorefice, Lorena, and Moiola, Lucia

Subjects
PREGNANCY outcomes, COVID-19 pandemic, PREGNANT women, MULTIPLE sclerosis, PREGNANCY complications
Abstract

Background: In the general population, maternal COVID-19 is associated with worse maternal and fetal outcomes. Two previous studies have assessed COVID-19 clinical outcomes in pregnant women with multiple sclerosis (MS), but there are no data about maternal and fetal outcomes. Objectives: In this multicenter study, we aimed to assess maternal and fetal outcomes in pregnant women with MS and COVID-19 infection. Methods: We recruited pregnant patients with MS who contracted COVID-19 and were followed up in Italian and Turkish Centers, during 2020–2022. A control group was extracted from a previous Italian cohort. Associations between group (COVID-19 or healthy patients) and clinical outcomes (maternal complications, fetal malformations, and spontaneous abortion) were investigated with a weighted logistic regression where propensity score–based inverse probability of treatment weighting (IPTW) approach was applied for adjusting for difference in baseline confounders. Results: In the multivariable analysis, COVID-19 during pregnancy was associated with a higher risk of maternal complications (odd ratio (OR) = 2.12; 95% confidence interval (CI) = 1.32–3.48; p = 0.002), while it was not associated with higher risk of spontaneous abortion and fetal malformations. Conclusion: Our data indicate that COVID-19 during pregnancy increases the risk of maternal complications, while it seems to have no significant impact on fetal outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study

Author

Ferraro, Diana, Annovazzi, Pietro, Moccia, Marcello, Lanzillo, Roberta, De Luca, Giovanna, Nociti, Viviana, Fantozzi, Roberta, Paolicelli, Damiano, Ragonese, Paolo, Gajofatto, Alberto, Boffa, Laura, Cavalla, Paola, Lo Fermo, Salvatore, Buscarinu, Maria Chiara, Lorefice, Lorena, Cordioli, Cinzia, Calabrese, Massimiliano, Gallo, Antonio, Pinardi, Federica, Tortorella, Carla, Di Filippo, Massimiliano, Camera, Valentina, Maniscalco, Giorgia Teresa, Radaelli, Marta, Buttari, Fabio, Tomassini, Valentina, Cocco, Eleonora, Gasperini, Claudio, and Solaro, Claudio

Published
2020
Full Text
View/download PDF

19. Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab

Author

Landi, Doriana, Grimaldi, Alfonso, Bovis, Francesca, Ponzano, Marta, Fantozzi, Roberta, Buttari, Fabio, Signoriello, Elisabetta, Lus, Giacomo, Lucchini, Matteo, Mirabella, Massimiliano, Cellerino, Maria, Inglese, Matilde, Cola, Gaia, Nicoletti, Carolina Gabri, Mataluni, Giorgia, Centonze, Diego, and Marfia, Girolama Alessandra

Published
2022
Full Text
View/download PDF

21. Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study

Author

Prosperini, Luca, Cortese, Antonio, Lucchini, Matteo, Boffa, Laura, Borriello, Giovanna, Buscarinu, Maria Chiara, Capone, Fioravante, Centonze, Diego, De Fino, Chiara, De Pascalis, Daniela, Fantozzi, Roberta, Ferraro, Elisabetta, Filippi, Maria, Galgani, Simonetta, Gasperini, Claudio, Haggiag, Shalom, Landi, Doriana, Marfia, Girolama, Mataluni, Giorgia, Millefiorini, Enrico, Mirabella, Massimiliano, Monteleone, Fabrizia, Nociti, Viviana, Pontecorvo, Simona, Romano, Silvia, Ruggieri, Serena, Salvetti, Marco, Tortorella, Carla, Zannino, Silvana, and Di Battista, Giancarlo

Published
2020
Full Text
View/download PDF

22. Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs

Author

Capuano, Rocco, primary, Prosperini, Luca, additional, Altieri, Manuela, additional, Lorefice, Lorena, additional, Fantozzi, Roberta, additional, Cavalla, Paola, additional, Guaschino, Clara, additional, Radaelli, Marta, additional, Cordioli, Cinzia, additional, Nociti, Viviana, additional, Boffa, Laura, additional, Ragonese, Paolo, additional, Di Gregorio, Maria, additional, Pinardi, Federica, additional, Torri Clerici, Valentina, additional, De Luca, Giovanna, additional, Gajofatto, Alberto, additional, Paolicelli, Damiano, additional, Tortorella, Carla, additional, Gasperini, Claudio, additional, Solaro, Claudio, additional, Cocco, Eleonora, additional, Bisecco, Alvino, additional, and Gallo, Antonio, additional

Published
2023
Full Text
View/download PDF

23. Frailty and relapse activity in multiple sclerosis: A longitudinal observation

Author

Baione, Viola, primary, Canevelli, Marco, additional, Belvisi, Daniele, additional, Buscarinu, Maria Chiara, additional, Bellucci, Gianmarco, additional, Fantozzi, Roberta, additional, Nicoletti, Carolina Gabri, additional, Malatuni, Giorgia, additional, Cortese, Antonio, additional, De Giglio, Laura, additional, Tartaglia, Matteo, additional, Ferrazzano, Gina, additional, Malimpensa, Leonardo, additional, Leodori, Giorgio, additional, Bruno, Giuseppe, additional, Ferraro, Elisabetta, additional, Marfia, Girolama Alessandra, additional, Centonze, Diego, additional, Salvetti, Marco, additional, and Conte, Antonella, additional

Published
2023
Full Text
View/download PDF

24. A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study

Author

Lanzillo, Roberta, Prosperini, Luca, Gasperini, Claudio, Moccia, Marcello, Fantozzi, Roberta, Tortorella, Carla, Nociti, Viviana, Annovazzi, Pietro, Cavalla, Paola, Radaelli, Marta, Malucchi, Simona, Clerici, Valentina Torri, Boffa, Laura, Buttari, Fabio, Ragonese, Paolo, Maniscalco, Giorgia Teresa, Di Filippo, Massimiliano, Buscarinu, Maria Chiara, Pinardi, Federica, Gallo, Antonio, Coghe, Giancarlo, Pesci, Ilaria, Laroni, Alice, Gajofatto, Alberto, Calabrese, Massimiliano, Tomassini, Valentina, Cocco, Eleonora, Solaro, Claudio, and R.I.Re.MS study group

Published
2018
Full Text
View/download PDF

26. “Better explanations” in multiple sclerosis diagnostic workup: A 3-year longitudinal study

Author

Calabrese, Massimiliano, Gasperini, Claudio, Tortorella, Carla, Schiavi, Gianmarco, Frisullo, Giovanni, Ragonese, Paolo, Fantozzi, Roberta, Prosperini, Luca, Annovazzi, Pietro, Cordioli, Cinzia, Di Filippo, Massimiliano, Ferraro, Diana, Gajofatto, Alberto, Malucchi, Simona, Lo Fermo, Salvatore, De Luca, Giovanna, Stromillo, Maria L., Cocco, Eleonora, Gallo, Antonio, Paolicelli, Damiano, Lanzillo, Roberta, Tomassini, Valentina, Pesci, Ilaria, Rodegher, Maria E., and Solaro, Claudio

Published
2019
Full Text
View/download PDF

28. Preventive exercise attenuates IL-2-driven mood disorders in multiple sclerosis

Author

Gilio, Luana, primary, Fresegna, Diego, additional, Gentile, Antonietta, additional, Guadalupi, Livia, additional, Sanna, Krizia, additional, De Vito, Francesca, additional, Balletta, Sara, additional, Caioli, Silvia, additional, Rizzo, Francesca Romana, additional, Musella, Alessandra, additional, Iezzi, Ennio, additional, Moscatelli, Alessandro, additional, Galifi, Giovanni, additional, Fantozzi, Roberta, additional, Bellantonio, Paolo, additional, Furlan, Roberto, additional, Finardi, Annamaria, additional, Vanni, Valentina, additional, Dolcetti, Ettore, additional, Bruno, Antonio, additional, Buttari, Fabio, additional, Mandolesi, Georgia, additional, Centonze, Diego, additional, and Stampanoni Bassi, Mario, additional

Published
2022
Full Text
View/download PDF

29. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis

Author

Landi, Doriana, primary, Bovis, Francesca, additional, Grimaldi, Alfonso, additional, Annovazzi, Pietro Osvaldo, additional, Bertolotto, Antonio, additional, Bianchi, Alessia, additional, Borriello, Giovanna, additional, Brescia Morra, Vincenzo, additional, Bucello, Sebastiano, additional, Buscarinu, Maria Chiara, additional, Caleri, Francesca, additional, Capobianco, Marco, additional, Capra, Ruggero, additional, Cellerino, Maria, additional, Centonze, Diego, additional, Cerqua, Raffaella, additional, Chisari, Clara Grazia, additional, Clerico, Marinella, additional, Cocco, Eleonora, additional, Cola, Gaia, additional, Cordioli, Cinzia, additional, Curti, Erica, additional, d'Ambrosio, Alessandro, additional, D'Amico, Emanuele, additional, De Luca, Giovanna, additional, Di Filippo, Massimiliano, additional, Di Lemme, Sonia, additional, Fantozzi, Roberta, additional, Ferraro, Diana, additional, Ferraro, Elisabetta, additional, Gallo, Antonio, additional, Gasperini, Claudio, additional, Granella, Franco, additional, Inglese, Matilde, additional, Lanzillo, Roberta, additional, Lorefice, Lorena, additional, Lus, Giacomo, additional, Malucchi, Simona, additional, Margoni, Monica, additional, Mataluni, Giorgia, additional, Mirabella, Massimiliano, additional, Moiola, Lucia, additional, Nicoletti, Carolina Gabri, additional, Nociti, Viviana, additional, Patti, Francesco, additional, Pinardi, Federica, additional, Portaccio, Emilio, additional, Pozzilli, Carlo, additional, Ragonese, Paolo, additional, Rasia, Sarah, additional, Salemi, Giuseppe, additional, Signoriello, Elisabetta, additional, Vitetta, Francesca, additional, Totaro, Rocco, additional, Sormani, Maria Pia, additional, Amato, Maria Pia, additional, and Marfia, Girolama Alessandra, additional

Published
2022
Full Text
View/download PDF

30. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study

Author

Prosperini, Luca, Lucchini, Matteo, Haggiag, Shalom, Bellantonio, Paolo, Bianco, Assunta, Buscarinu, Maria Chiara, Buttari, Fabio, Centonze, Diego, Cortese, Antonio, De Giglio, Laura, Fantozzi, Roberta, Ferraro, Elisabetta, Fornasiero, Arianna, Francia, Ada, Galgani, Simonetta, Gasperini, Claudio, Marfia, Girolama Alessandra, Millefiorini, Enrico, Nociti, Viviana, Pontecorvo, Simona, Pozzilli, Carlo, Ruggieri, Serena, Salvetti, Marco, Sgarlata, Eleonora, and Mirabella, Massimiliano

Published
2018
Full Text
View/download PDF

32. Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection

Author

Landi, Doriana, primary, Cola, Gaia, additional, Mantero, Vittorio, additional, Balgera, Roberto, additional, Moiola, Lucia, additional, Nozzolillo, Agostino, additional, Dattola, Vincenzo, additional, Sinisi, Leonardo, additional, Fantozzi, Roberta, additional, Di Lemme, Sonia, additional, Centonze, Diego, additional, Mataluni, Giorgia, additional, Nicoletti, Carolina Gabri, additional, and Marfia, Girolama Alessandra, additional

Published
2022
Full Text
View/download PDF

33. Cerebrospinal fluid levels of L‐glutamate signal central inflammatory neurodegeneration in multiple sclerosis

Author

Stampanoni Bassi, Mario, primary, Nuzzo, Tommaso, additional, Gilio, Luana, additional, Miroballo, Mattia, additional, Casamassa, Alessia, additional, Buttari, Fabio, additional, Bellantonio, Paolo, additional, Fantozzi, Roberta, additional, Galifi, Giovanni, additional, Furlan, Roberto, additional, Finardi, Annamaria, additional, De Rosa, Arianna, additional, Di Maio, Anna, additional, Errico, Francesco, additional, Centonze, Diego, additional, and Usiello, Alessandro, additional

Published
2021
Full Text
View/download PDF

34. Age at Disease Onset Associates With Oxidative Stress, Neuroinflammation, and Impaired Synaptic Plasticity in Relapsing-Remitting Multiple Sclerosis

Author

Stampanoni Bassi, Mario, primary, Gilio, Luana, additional, Iezzi, Ennio, additional, Moscatelli, Alessandro, additional, Pekmezovic, Tatjana, additional, Drulovic, Jelena, additional, Furlan, Roberto, additional, Finardi, Annamaria, additional, Mandolesi, Georgia, additional, Musella, Alessandra, additional, Galifi, Giovanni, additional, Fantozzi, Roberta, additional, Bellantonio, Paolo, additional, Storto, Marianna, additional, Centonze, Diego, additional, and Buttari, Fabio, additional

Published
2021
Full Text
View/download PDF

35. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis

Author

Di Filippo, Massimiliano, primary, Cordioli, Cinzia, additional, Malucchi, Simona, additional, Annovazzi, Pietro, additional, Cavalla, Paola, additional, Torri Clerici, Valentina, additional, Ragonese, Paolo, additional, Nociti, Viviana, additional, Radaelli, Marta, additional, Laroni, Alice, additional, Buttari, Fabio, additional, Lorefice, Lorena, additional, Ferraro, Diana, additional, Gajofatto, Alberto, additional, Prosperini, Luca, additional, Fantozzi, Roberta, additional, Boffa, Laura, additional, Lanzillo, Roberta, additional, Moccia, Marcello, additional, Clerico, Marinella, additional, De Luca, Giovanna, additional, Tomassini, Valentina, additional, Calabrese, Massimiliano, additional, Borrelli, Angela, additional, Paolicelli, Damiano, additional, Maniscalco, Giorgia Teresa, additional, Gazzola, Paola, additional, Gallo, Antonio, additional, Solaro, Claudio, additional, Cocco, Eleonora, additional, Gasperini, Claudio, additional, and Tortorella, Carla, additional

Published
2021
Full Text
View/download PDF

37. sj-pdf-2-msj-10.1177_1352458520987541 – Supplemental material for Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation

Author

Belvisi, Daniele, Canevelli, Marco, Baione, Viola, Buscarinu, Maria Chiara, Pellicciari, Giulia, Fantozzi, Roberta, Creta, Armando, Cecchi, Gianluca, Cola, Gaia, Nicoletti, Carolina Gabri, Cortese, Antonio, Giglio, Laura De, Tartaglia, Matteo, Crisafulli, Sebastiano Giuseppe, Bruno, Giuseppe, Ferraro, Elisabetta, Marfia, Girolama Alessandra, Centonze, Diego, Salvetti, Marco, and Conte, Antonella

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-pdf-2-msj-10.1177_1352458520987541 for Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation by Daniele Belvisi, Marco Canevelli, Viola Baione, Maria Chiara Buscarinu, Giulia Pellicciari, Roberta Fantozzi, Armando Creta, Gianluca Cecchi, Gaia Cola, Carolina Gabri Nicoletti, Antonio Cortese, Laura De Giglio, Matteo Tartaglia, Sebastiano Giuseppe Crisafulli, Giuseppe Bruno, Elisabetta Ferraro, Girolama Alessandra Marfia, Diego Centonze, Marco Salvetti and Antonella Conte in Multiple Sclerosis Journal

Published
2021
Full Text
View/download PDF

38. sj-pdf-1-msj-10.1177_1352458520987541 – Supplemental material for Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation

Author

Belvisi, Daniele, Canevelli, Marco, Baione, Viola, Buscarinu, Maria Chiara, Pellicciari, Giulia, Fantozzi, Roberta, Creta, Armando, Cecchi, Gianluca, Cola, Gaia, Nicoletti, Carolina Gabri, Cortese, Antonio, Giglio, Laura De, Tartaglia, Matteo, Crisafulli, Sebastiano Giuseppe, Bruno, Giuseppe, Ferraro, Elisabetta, Marfia, Girolama Alessandra, Centonze, Diego, Salvetti, Marco, and Conte, Antonella

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-pdf-1-msj-10.1177_1352458520987541 for Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation by Daniele Belvisi, Marco Canevelli, Viola Baione, Maria Chiara Buscarinu, Giulia Pellicciari, Roberta Fantozzi, Armando Creta, Gianluca Cecchi, Gaia Cola, Carolina Gabri Nicoletti, Antonio Cortese, Laura De Giglio, Matteo Tartaglia, Sebastiano Giuseppe Crisafulli, Giuseppe Bruno, Elisabetta Ferraro, Girolama Alessandra Marfia, Diego Centonze, Marco Salvetti and Antonella Conte in Multiple Sclerosis Journal

Published
2021
Full Text
View/download PDF

39. Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing–Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)

Author

Centonze, Diego, primary, Fantozzi, Roberta, additional, Buttari, Fabio, additional, Grimaldi, Luigi Maria Edoardo, additional, Totaro, Rocco, additional, Corea, Francesco, additional, Marrosu, Maria Giovanna, additional, Confalonieri, Paolo, additional, Cottone, Salvatore, additional, Trojano, Maria, additional, and Zipoli, Valentina, additional

Published
2021
Full Text
View/download PDF

40. Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation

Author

Belvisi, Daniele, primary, Canevelli, Marco, additional, Baione, Viola, additional, Buscarinu, Maria Chiara, additional, Pellicciari, Giulia, additional, Fantozzi, Roberta, additional, Creta, Armando, additional, Cecchi, Gianluca, additional, Cola, Gaia, additional, Nicoletti, Carolina Gabri, additional, Cortese, Antonio, additional, De Giglio, Laura, additional, Tartaglia, Matteo, additional, Crisafulli, Sebastiano Giuseppe, additional, Bruno, Giuseppe, additional, Ferraro, Elisabetta, additional, Marfia, Girolama Alessandra, additional, Centonze, Diego, additional, Salvetti, Marco, additional, and Conte, Antonella, additional

Published
2021
Full Text
View/download PDF

41. Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study

Author

Di Gregorio, Maria, primary, Torri Clerici, Valentina Liliana Adriana, additional, Fenu, Giuseppe, additional, Gaetani, Lorenzo, additional, Gallo, Antonio, additional, Cavalla, Paola, additional, Ragonese, Paolo, additional, Annovazzi, Pietro, additional, Gajofatto, Alberto, additional, Prosperini, Luca, additional, Landi, Doriana, additional, Nicoletti, Carolina Gabri, additional, Di Carmine, Caterina, additional, Totaro, Rocco, additional, Nociti, Viviana, additional, De Fino, Chiara, additional, Ferraro, Diana, additional, Tomassini, Valentina, additional, Tortorella, Carla, additional, Righini, Isabella, additional, Amato, Maria Pia, additional, Manni, Alessia, additional, Paolicelli, Damiano, additional, Iaffaldano, Pietro, additional, Lanzillo, Roberta, additional, Moccia, Marcello, additional, Buttari, Fabio, additional, Fantozzi, Roberta, additional, Cerqua, Raffaella, additional, Zagaglia, Sara, additional, Farina, Deborah, additional, De Luca, Giovanna, additional, Buscarinu, Maria Chiara, additional, Pinardi, Federica, additional, Cocco, Eleonora, additional, Gasperini, Claudio, additional, Solaro, Claudio Marcello, additional, and Di Filippo, Massimiliano, additional

Published
2021
Full Text
View/download PDF

42. sj-pdf-1-tan-10.1177_1756286420970833 – Supplemental material for Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients

Author

Bassi, Mario Stampanoni, Drulovic, Jelena, Pekmezovic, Tatjana, Iezzi, Ennio, Sica, Francesco, Gilio, Luana, Gentile, Antonietta, Musella, Alessandra, Mandolesi, Georgia, Furlan, Roberto, Finardi, Annamaria, Marfia, Girolama Alessandra, Bellantonio, Paolo, Fantozzi, Roberta, Centonze, Diego, and Buttari, Fabio

Subjects
FOS: Clinical medicine, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-pdf-1-tan-10.1177_1756286420970833 for Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients by Mario Stampanoni Bassi, Jelena Drulovic, Tatjana Pekmezovic, Ennio Iezzi, Francesco Sica, Luana Gilio, Antonietta Gentile, Alessandra Musella, Georgia Mandolesi, Roberto Furlan, Annamaria Finardi, Girolama Alessandra Marfia, Paolo Bellantonio, Roberta Fantozzi, Diego Centonze and Fabio Buttari in Therapeutic Advances in Neurological Disorders

Published
2020
Full Text
View/download PDF

44. Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study)

Author

Patti, Francesco, primary, Chisari, Clara Grazia, additional, D'Amico, Emanuele, additional, Annovazzi, Pietro, additional, Banfi, Paola, additional, Bergamaschi, Roberto, additional, Clerici, Raffaella, additional, Conti, Marta Zaffira, additional, Cortese, Antonio, additional, Fantozzi, Roberta, additional, Fischetti, Mariano, additional, Frigo, Maura, additional, Gatto, Maurizia, additional, Immovilli, Paolo, additional, Leoni, Stefania, additional, Malucchi, Simona, additional, Maniscalco, Giorgia, additional, Marfia, Girolama Alessandra, additional, Paolicelli, Damiano, additional, Perini, Paola, additional, Serrati, Carlo, additional, Sola, Patrizia, additional, Totaro, Rocco, additional, Turano, Gabriella, additional, Valentino, Paola, additional, Zaffaroni, Mauro, additional, Zuliani, Cristina, additional, and Centonze, Diego, additional

Published
2020
Full Text
View/download PDF

45. Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients

Author

Stampanoni Bassi, Mario, primary, Drulovic, Jelena, additional, Pekmezovic, Tatjana, additional, Iezzi, Ennio, additional, Sica, Francesco, additional, Gilio, Luana, additional, Gentile, Antonietta, additional, Musella, Alessandra, additional, Mandolesi, Georgia, additional, Furlan, Roberto, additional, Finardi, Annamaria, additional, Marfia, Girolama Alessandra, additional, Bellantonio, Paolo, additional, Fantozzi, Roberta, additional, Centonze, Diego, additional, and Buttari, Fabio, additional

Published
2020
Full Text
View/download PDF

46. Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study

Author

Prosperini, Luca, primary, Cortese, Antonio, additional, Lucchini, Matteo, additional, Boffa, Laura, additional, Borriello, Giovanna, additional, Buscarinu, Maria Chiara, additional, Capone, Fioravante, additional, Centonze, Diego, additional, De Fino, Chiara, additional, De Pascalis, Daniela, additional, Fantozzi, Roberta, additional, Ferraro, Elisabetta, additional, Filippi, Maria, additional, Galgani, Simonetta, additional, Gasperini, Claudio, additional, Haggiag, Shalom, additional, Landi, Doriana, additional, Marfia, Girolama, additional, Mataluni, Giorgia, additional, Millefiorini, Enrico, additional, Mirabella, Massimiliano, additional, Monteleone, Fabrizia, additional, Nociti, Viviana, additional, Pontecorvo, Simona, additional, Romano, Silvia, additional, Ruggieri, Serena, additional, Salvetti, Marco, additional, Tortorella, Carla, additional, Zannino, Silvana, additional, and Di Battista, Giancarlo, additional

Published
2019
Full Text
View/download PDF

47. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis.

Author

Di Filippo, Massimiliano, Cordioli, Cinzia, Malucchi, Simona, Annovazzi, Pietro, Cavalla, Paola, Clerici, Valentina Torri, Ragonese, Paolo, Nociti, Viviana, Radaelli, Marta, Laroni, Alice, Buttari, Fabio, Lorefce, Lorena, Ferraro, Diana, Gajofatto, Alberto, Prosperini, Luca, Fantozzi, Roberta, Boffa, Laura, Lanzillo, Roberta, Moccia, Marcello, and Clerico, Marinella

Subjects
DISEASE relapse, MULTIPLE sclerosis, COVID-19 vaccines, MEDICAL personnel, COVID-19 pandemic, DISEASE duration
Published
2022
Full Text
View/download PDF

48. Fingolimod vs dimethyl fumarate in multiple sclerosis

Author

Prosperini, Luca, Lucchini, Matteo, Haggiag, Shalom, Bellantonio, Paolo, Bianco, Assunta, Buscarinu, Maria Chiara, Buttari, Fabio, Centonze, Diego, Cortese, Antonio, De Giglio, Laura, Fantozzi, Roberta, Ferraro, Elisabetta, Fornasiero, Arianna, Francia, Ada, Galgani, Simonetta, Gasperini, Claudio, Marfia, Girolama Alessandra, Millefiorini, Enrico, Nociti, Viviana, Pontecorvo, Simona, Pozzilli, Carlo, Ruggieri, Serena, Salvetti, Marco, Sgarlata, Eleonora, and Mirabella, Massimiliano

Subjects
Multiple sclerosis, case control), Settore MED/26 - NEUROLOGIA, Multiple sclerosis, class IV, clinical trials observational studies (Cohort, case control), class IV, clinical trials observational studies (Cohort
Published
2018

49. Obesity worsens central inflammation and disability in multiple sclerosis

Author

Stampanoni Bassi, Mario, primary, Iezzi, Ennio, additional, Buttari, Fabio, additional, Gilio, Luana, additional, Simonelli, Ilaria, additional, Carbone, Fortunata, additional, Micillo, Teresa, additional, De Rosa, Veronica, additional, Sica, Francesco, additional, Furlan, Roberto, additional, Finardi, Annamaria, additional, Fantozzi, Roberta, additional, Storto, Marianna, additional, Bellantonio, Paolo, additional, Pirollo, Pamela, additional, Di Lemme, Sonia, additional, Musella, Alessandra, additional, Mandolesi, Georgia, additional, Centonze, Diego, additional, and Matarese, Giuseppe, additional

Published
2019
Full Text
View/download PDF

50. Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients

Author

Sessa Edoardo, Solda' Annalisa, Locatelli Laura, Fantozzi Roberta, Picconi Orietta, De Luca Giovanna, Bellantonio Paolo, Amato Mariapia, Bramanti Placido, Lugaresi Alessandra, Durastanti Valentina, Totaro Rocco, Marino Silvia, Zipoli Valentina, Zorzon Marino, and Millefiorini Enrico

Subjects
Medicine
Abstract

Background Increased synthesis of neopterin and degradation of tryptophan to kynurenine, measured as kynurenine/tryptophan ratio (kyn/trp ratio), are considered in vitro markers of interferon beta-1a (IFNβ-1a) activity. The aim of the study was to investigate the dynamic profile of neopterin and kyn/trp ratio in patients with relapsing remitting multiple sclerosis (RRMS) treated with two different doses of IFNβ-1a over a period of 24 months. Methods RRMS patients (n = 101) received open-label IFNβ-1a 22 mcg (low dose, LD) or 44 mcg (high dose, HD) subcutaneously (sc), three times weekly for 24 months. Serum measurements of neopterin, kyn/trp ratio and neutralizing antibodies (NAbs) were obtained before treatment (i.e., at baseline) and 48 hours post-injection every 3 months thereafter. Clinical assessments were performed at baseline and every 6 months. Changes in biomarkers over time were compared between LD- and HD-group as well as between patients with/without relapses and with/without NAbs using Analysis of Variance and Mann-Whitney tests. Results Neopterin (p < 0.001) and kyn/trp ratio (p = 0.0013) values increased over time vs baseline in both treatment groups. Neopterin values were higher (p = 0.046) in the HD-compared to the LD-group at every time point with the exclusion of months 21 and 24 of therapy. Conversely, there were no differences between the two doses groups in the kyn/trp ratio with the exclusion of month 6 of therapy (p < 0.05). Neopterin levels were significantly reduced in NAb-positive patients starting from month 9 of therapy (p < 0.05); the same result was observed for kyn/trp ratio but only at month 9 (p = 0.02). Clinical status did not significantly affect neopterin production and tryptophan degradation. Conclusions Although differences in serum markers concentration were found following IFNβ administration the clinical relevance of these findings needs to be confirmed with more detailed studies.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results